NCT07849985

Brief Summary

Conduct Disorder (CD) is a common psychiatric disorder among children and adolescents and is characterized by a persistent pattern of behaviors that violate the rights of others or major age-appropriate social norms and rules. Although CD is traditionally classified as an externalizing disorder, evidence suggests that some affected adolescents also show abnormalities in emotional and motivational processing, particularly in reward and punishment responsiveness. Anhedonia, defined as reduced ability to experience pleasure, is traditionally considered a core symptom of depression but is increasingly recognized as a transdiagnostic construct that may reflect disturbances in reward processing. Importantly, altered reward responsiveness is not synonymous with clinical anhedonia, and clinically measured anhedonia in adolescents with CD remains insufficiently characterized. Depressive symptoms may contribute to anhedonia and therefore require assessment and statistical control. ADHD is also frequently comorbid with CD and may independently influence reward processing and motivation. Callous-Unemotional traits may additionally overlap with emotional blunting. Therefore, the present study will compare anhedonia in adolescents with CD with or without comorbid ADHD, and healthy controls, while accounting for depressive symptoms and relevant clinical covariates.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
14mo left

Started Oct 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress1%
Oct 2026Dec 2027

First Submitted

Initial submission to the registry

September 24, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 30, 2026

Completed
1 day until next milestone

Study Start

First participant enrolled

October 1, 2026

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2026

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Expected
Last Updated

September 30, 2026

Status Verified

September 1, 2026

Enrollment Period

Same day

First QC Date

September 24, 2026

Last Update Submit

September 24, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • SHAPS total score

    SHAPS total score, representing overall anhedonia severity

    baseline

Study Arms (2)

cases group

Participants meeting criteria for Conduct Disorder

control group

healthy control

Eligibility Criteria

Age12 Years - 17 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

Participants aged 12-17 years will be recruited consecutively from the outpatient child and adolescent psychiatry service. Participants meeting criteria for Conduct Disorder will form the clinical group. Healthy controls of comparable age, sex, and socioeconomic status will be recruited from community or school settings. ADHD comorbidity will be assessed within the Conduct Disorder group

You may qualify if:

  • Age 12-17 years.
  • CD groups: meeting DSM-5 criteria for Conduct Disorder confirmed using the Arabic K-SADS-PL-C DSM-5.
  • Control group: no current or previous psychiatric diagnosis according to the Arabic K-SADS-PL-C DSM-5.
  • Ability to understand and complete the assessment procedures.
  • Written informed consent from a parent/legal guardian and written assent from the adolescent.

You may not qualify if:

  • Intellectual disability or severe cognitive impairment interfering with reliable assessment.
  • Autism spectrum disorder or severe neurodevelopmental disorder interfering with self-report.
  • Current psychotic disorder.
  • Current or past bipolar I disorder or manic episode.
  • Current major depressive episode meeting full diagnostic criteria.
  • Current severe substance use disorder.
  • Known neurological disorder, including epilepsy or severe traumatic brain injury.
  • Major uncontrolled medical condition likely to substantially affect mood or hedonic functioning.
  • Current medication expected to substantially affect reward processing or anhedonia, where clinically relevant.
  • Acute suicidal risk or psychiatric condition requiring immediate crisis intervention/hospitalization.
  • Refusal to participate or inability to complete the assessment. Stable stimulant treatment for ADHD may be permitted when clinically necessary and will be recorded as a covariate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Conduct DisorderDepression

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental DisordersBehavioral SymptomsBehavior

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
residant doctor at Assiut university hospital

Study Record Dates

First Submitted

September 24, 2026

First Posted

September 30, 2026

Study Start

October 1, 2026

Primary Completion

October 1, 2026

Study Completion (Estimated)

December 1, 2027

Last Updated

September 30, 2026

Record last verified: 2026-09